Skip to content
drillr.ai

ABT

Abbott Laboratories

NYSE · USHealthcareMedical - Devices
$101.72+1.03%

Price as of Jul 20, 2026

ABT news

Abbott Laboratories news

A server-rendered, paginated timeline of the latest available company news.

  1. New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents

    New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents PR Newswire ABBOTT PARK, Ill., June 22, 2026 * Despite optimism about parenthood, unrealistic online portrayals are adding pressure for today's young parents * Through the new "Love Without Measure" initiative, Similac is standing with parents in promoting more authentic portrayals of parenthood and pushing back on comparison culture ABBOTT PARK, Ill., Ju

    PR Newswire ·

  2. Abbott declares 410th consecutive quarterly dividend

    Abbott declares 410th consecutive quarterly dividend PR Newswire ABBOTT PARK, Ill., June 12, 2026 ABBOTT PARK, Ill., June 12, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 410(th) consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 17, 2026, to shareholders of record at the close of business on July 15, 2026. Abbott has increased its dividend pay

    PR Newswire ·

  3. New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers

    New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers PR Newswire NEW ORLEANS, June 8, 2026 * Study at ADA's Scientific Sessions shows participants in Abbott's Healthy Food Rx program combined with health coaching had significant health improvements * Abbott's Healthy Food Rx program is a Food is Medicine initiative delivering recipe-based food boxes and nutrition education to people living wi

    PR Newswire ·

  4. Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

    Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes PR Newswire ABBOTT PARK, Ill., May 28, 2026 * First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetes * Integrates with the Libre digital health ecosystem, allowing people to share

    PR Newswire ·

  5. ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

    ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening PR Newswire ABBOTT PARK, Ill., May 27, 2026 * Cologuard(®) and Cologuard Plus(®) reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guideline * Abbott to offer only CRC screening portfolio aligned to new ACS recommendations combining preferred stool-based plus additional blood-based options * Recent publications support Cologuard-first strat

    PR Newswire ·

  6. Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

    Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026 PR Newswire ABBOTT PARK, Ill., May 26, 2026 * Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission * New MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancer * Early MCED prospective data show low anxiety and minimal psychological burden in real-wor

    PR Newswire ·

  7. Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform

    Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform PR Newswire ABBOTT PARK, Ill., April 28, 2026 * Ultreon 3.0 is the first advanced optical coherence tomography (OCT) system in the U.S. and Europe that integrates high resolution coronary plaque images and AI-automated insights through the artery * The integrated imaging platform is designed to enable fast, intuitive decision making for physicians while treating complex coronary d

    PR Newswire ·

  8. Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

    Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 PR Newswire ABBOTT PARK, Ill., April 25, 2026 * Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfolios * Six-month results from the FlexPulse IDE study for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, reveal

    PR Newswire ·

  9. New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test

    New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test PR Newswire ABBOTT PARK, Ill., April 17, 2026 * Data show how a multi-biomarker class approach improves early-stage cancer detection * AACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical impact of MCED ABBOTT PARK, Ill., April 17, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present new data at the American Association for Cancer Rese

    PR Newswire ·

  10. Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

    Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences PR Newswire ABBOTT PARK, Ill., April 16, 2026 * First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percent * Completed acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics market * Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%(1) * Abbott projects full-year 2026 adjusted dil

    PR Newswire ·

  11. New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health

    New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health PR Newswire ABBOTT PARK, Ill., April 9, 2026 With chronic disease on the rise, a new survey from Abbott shows information overload, confusion and cost leave many Americans struggling, worrying about how to stay healthy ABBOTT PARK, Ill., April 9, 2026 /PRNewswire/ -- Today, Abbott (NYSE: ABT), a global leader in chronic disease prevention, treatment and care, i

    PR Newswire ·

  12. John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening

    John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening PR Newswire ABBOTT PARK, Ill., March 24, 2026 * Potentially awkward conversations and 90s nostalgia combine to drive accessible screening for adults 45+ * Learn more at Cologuard.com/TheTalk (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4647764-1&h=563230033&u=https%3A%2F%2Fwww.cologuard.com%2Fthe-second-talk%3Futm_source%3Dfbig%26utm_medium%3Dpaid_social%26utm_campaign%3Dcg_

    PR Newswire ·

  13. Abbott completes acquisition of Exact Sciences

    Abbott completes acquisition of Exact Sciences PR Newswire ABBOTT PARK, Ill., March 23, 2026 * Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments * Advances Abbott's mission to make healthcare more accessible and give people more control over their health ABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and

    PR Newswire ·

  14. Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

    Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management PR Newswire ABBOTT PARK, Ill., March 12, 2026 * U.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks (1,2) * Improvements were participant-led, using real-time glucose readings to guide everyday decisions * Complementary Italian study reported simi

    PR Newswire ·